Nuclear Medicine Radioisotopes Market Analysis by Radioisotope Type (Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123)), by Application (Cardiology, Oncology). , neurology, lymphoma, thyroid), by end user (hospitals, diagnostic centers)

Rockville, Maryland, United States, January 24, 2023 – According to a new industry analysis by Fact.MR, a provider of market research and competitive intelligence, the global market for nuclear medicine radioisotopes is valued at US$8.82 billion in 2023 and is projected to reach US$19.04 billion by the end of 2033 .

Medical radioisotopes are harmless radioactive compounds typically used in the diagnosis of medical conditions. These radioisotopes release gamma rays strong enough to leave the body when used to diagnose a disease.

Download a free sample copy of this report: https://www.factmr.com/connectus/sample?flag=S&rep_id=8311?kw

The number of nuclear medicine radioisotopes is expected to increase rapidly during the forecast period due to the rising rate of cancer cases and growing public knowledge about nuclear therapies. A radiopharmaceutical is a pharmaceutical formulation containing radioactive isotopes used for diagnosis and treatment. They are small, simple radioactive compounds used to treat cancer, heart and neurological diseases.

In oncology and cancer treatment, therapeutic radioisotopes are replacing traditional chemotherapy procedures because they are more convenient, creating further new opportunities in the nuclear medicine radioisotope market. In addition, compared to X-rays and other external radiation imaging systems, radioisotopes serve as an accurate and safe alternative for patients and assist physicians in diagnosis.

The technetium-99 radioisotope is expected to account for a significant share of the global market in 2023 due to its increasing use in diagnostics.

• The World Nuclear Organization estimates that around 40 million…